← Back

Wire · regulatory

FDA Approves Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention

Published

10 November 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at neurologylive.com →

◆ Verified

Fusion42 · 10 November 2026 · Fusion42 review

The FDA has approved Bayer's asundexian, the first oral factor XIa inhibitor, to reduce recurrent stroke risk in adults after noncardioembolic ischemic stroke or high-risk TIA, based on positive phase 3 trial results showing reduced ischemic stroke without significant major bleeding increase.

This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.

◆ ◆ The Wire takeaway

You face a new treatment option approved for secondary stroke prevention that lowers recurrent strokes without raising major bleeding risks. Update your clinical and partner strategies to reflect this advance in oral anticoagulants.

◆ Coverage

15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalstroke-preventionfactor-xia-inhibitorbayerasundexian